125 related articles for article (PubMed ID: 21474491)
1. Docking-based virtual screening of potential human P2Y12 receptor antagonists.
Chen H; Dong X; Zhou M; Shi H; Luo X
Acta Biochim Biophys Sin (Shanghai); 2011 May; 43(5):400-8. PubMed ID: 21474491
[TBL] [Abstract][Full Text] [Related]
2. Molecular mechanism of action for reversible P2Y12 antagonists.
Liu H; Ge H; Peng Y; Xiao P; Xu J
Biophys Chem; 2011 May; 155(2-3):74-81. PubMed ID: 21440362
[TBL] [Abstract][Full Text] [Related]
3. Combined 3D-QSAR, molecular docking, and molecular dynamics study on piperazinyl-glutamate-pyridines/pyrimidines as potent P2Y12 antagonists for inhibition of platelet aggregation.
Hao M; Li Y; Wang Y; Yan Y; Zhang S; Li G; Yang L
J Chem Inf Model; 2011 Oct; 51(10):2560-72. PubMed ID: 21923153
[TBL] [Abstract][Full Text] [Related]
4. Identification and analysis of functionally important amino acids in human purinergic 12 receptor using a Saccharomyces cerevisiae expression system.
Ignatovica V; Megnis K; Lapins M; Schiöth HB; Klovins J
FEBS J; 2012 Jan; 279(1):180-91. PubMed ID: 22044483
[TBL] [Abstract][Full Text] [Related]
5. Molecular modeling of purinergic receptor P2Y12 and interaction with its antagonists.
Zhan C; Yang J; Dong XC; Wang YL
J Mol Graph Model; 2007 Jul; 26(1):20-31. PubMed ID: 17110146
[TBL] [Abstract][Full Text] [Related]
6. Ticagrelor effectively and reversibly blocks murine platelet P2Y12-mediated thrombosis and demonstrates a requirement for sustained P2Y12 inhibition to prevent subsequent neointima.
Patil SB; Jackman LE; Francis SE; Judge HM; Nylander S; Storey RF
Arterioscler Thromb Vasc Biol; 2010 Dec; 30(12):2385-91. PubMed ID: 21071697
[TBL] [Abstract][Full Text] [Related]
7. Regulation of functionally active P2Y12 ADP receptors by thrombin in human smooth muscle cells and the presence of P2Y12 in carotid artery lesions.
Rauch BH; Rosenkranz AC; Ermler S; Böhm A; Driessen J; Fischer JW; Sugidachi A; Jakubowski JA; Schrör K
Arterioscler Thromb Vasc Biol; 2010 Dec; 30(12):2434-42. PubMed ID: 21071695
[TBL] [Abstract][Full Text] [Related]
8. Prediction of P2Y12 antagonists using a novel genetic algorithm-support vector machine coupled approach.
Hao M; Li Y; Wang Y; Zhang S
Anal Chim Acta; 2011 Mar; 690(1):53-63. PubMed ID: 21414436
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of ticagrelor derivatives as novel antiplatelet agents.
Zhang H; Liu J; Zhang L; Kong L; Yao H; Sun H
Bioorg Med Chem Lett; 2012 Jun; 22(11):3598-602. PubMed ID: 22546677
[TBL] [Abstract][Full Text] [Related]
10. Investigating the binding mechanism of novel 6-aminonicotinate-based antagonists with P2Y
Zhou S; Fang D; Tan S; Lin W; Wu W; Zheng K
J Biomol Struct Dyn; 2017 Oct; 35(13):2938-2965. PubMed ID: 27634290
[TBL] [Abstract][Full Text] [Related]
11. Protein-based virtual screening of chemical databases. II. Are homology models of G-Protein Coupled Receptors suitable targets?
Bissantz C; Bernard P; Hibert M; Rognan D
Proteins; 2003 Jan; 50(1):5-25. PubMed ID: 12471595
[TBL] [Abstract][Full Text] [Related]
12. First pharmacophore model of CCR3 receptor antagonists and its homology model-assisted, stepwise virtual screening.
Jain V; Saravanan P; Arvind A; Mohan CG
Chem Biol Drug Des; 2011 May; 77(5):373-87. PubMed ID: 21284830
[TBL] [Abstract][Full Text] [Related]
13. BF0801, a novel adenine derivative, inhibits platelet activation via phosphodiesterase inhibition and P2Y12 antagonism.
Zhang S; Hu L; Du H; Guo Y; Zhang Y; Niu H; Jin J; Zhang J; Liu J; Zhang X; Kunapuli SP; Ding Z
Thromb Haemost; 2010 Oct; 104(4):845-57. PubMed ID: 20806121
[TBL] [Abstract][Full Text] [Related]
14. Identification of high-affinity P2Y₁₂ antagonists based on a phenylpyrazole glutamic acid piperazine backbone.
Zech G; Hessler G; Evers A; Weiss T; Florian P; Just M; Czech J; Czechtizky W; Görlitzer J; Ruf S; Kohlmann M; Nazaré M
J Med Chem; 2012 Oct; 55(20):8615-29. PubMed ID: 22984835
[TBL] [Abstract][Full Text] [Related]
15. Homology model-based virtual screening for GPCR ligands using docking and target-biased scoring.
Radestock S; Weil T; Renner S
J Chem Inf Model; 2008 May; 48(5):1104-17. PubMed ID: 18442221
[TBL] [Abstract][Full Text] [Related]
16. Are P2Y12 reaction unit (PRU) and % inhibition index equivalent for the expression of P2Y12 inhibition by the VerifyNow assay? Role of haematocrit and haemoglobin levels.
Voisin S; Bongard V; Tidjane MA; Lhermusier T; Carrié D; Sié P
Thromb Haemost; 2011 Aug; 106(2):227-9. PubMed ID: 21544318
[TBL] [Abstract][Full Text] [Related]
17. Ticagrelor for the treatment of arterial thrombosis.
Gurbel PA; Kereiakes DJ; Tantry US
Expert Opin Pharmacother; 2010 Sep; 11(13):2251-9. PubMed ID: 20707759
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of cyclopentyl-triazolol-pyrimidine (CPTP) based P2Y12 antagonists.
Tu W; Fan J; Zhang H; Xu G; Liu Z; Qu J; Yang F; Zhang L; Luan T; Yuan J; Gong A; Feng J; Sun P; Dong Q
Bioorg Med Chem Lett; 2014 Jan; 24(1):141-6. PubMed ID: 24332627
[TBL] [Abstract][Full Text] [Related]
19. Three-dimensional model of the human urotensin-II receptor: docking of human urotensin-II and nonpeptide antagonists in the binding site and comparison with an antagonist pharmacophore model.
Lescot E; Sopkova-de Oliveira Santos J; Colloc'h N; Rodrigo J; Milazzo-Segalas I; Bureau R; Rault S
Proteins; 2008 Oct; 73(1):173-84. PubMed ID: 18409194
[TBL] [Abstract][Full Text] [Related]
20. Pharmacology and clinical trials of reversibly-binding P2Y12 inhibitors.
Storey RF
Thromb Haemost; 2011 May; 105 Suppl 1():S75-81. PubMed ID: 21479343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
